v3.25.2
Summary of Significant Accounting Policies (Details) - USD ($)
 6 Months Ended 12 Months Ended
Mar. 31, 2023
Jun. 30, 2024
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2025
Summary of Significant Accounting Policies [Line Items]                
Allowance for credit losses       $ 522,191   $ 521,007    
Written-down of inventories         13,206  
Estimated useful life       5 years        
Lease term       12 months       8 months 12 days
Government subsidies       $ 900,000   100,000 300,000  
Vesting period term 6 months              
Management approach to determine reportable segments description       The Group operates and manages its business as a single operating and reportable segment. The Group’s CODM has been identified as the Chief Executive Officer who reviews the consolidated net income (loss) when making decisions about allocating resources and assessing performance of the Group.        
Executive Chairman       Executive Chairman        
Cash equivalents       $ 874,238   2,005,351 $ 1,882,545  
Impairment charges on long-lived assets   $ 128,128       $ 519,496    
DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
Management approach to determine reportable segments description     The Company performs research and development activities of its own and for others substantially in one location using resources common to internal research activities and revenue-producing services, which have been limited to date.          
Executive Chairman     Executive Chairman          
Cash equivalents            
FDIC insured limits     250,000          
Impairment charges on long-lived assets            
Minimum [Member]                
Summary of Significant Accounting Policies [Line Items]                
Vesting period term       9 months 15 days        
Maximum [Member]                
Summary of Significant Accounting Policies [Line Items]                
Vesting period term       21 months 15 days        
Unbilled Revenues [Member] | DiamiR Biosciences Corp. [Member]                
Summary of Significant Accounting Policies [Line Items]                
Contract asset       $ 89,281